Rocket Pharma Reports Positive Safety Data for RP-A501 in Phase 2 Danon Disease Trial

Rocket Pharmaceuticals announced a positive clinical safety update for its pivotal Phase 2 trial of RP-A501, an investigational gene therapy for Danon disease. The initial three patients treated under a modified protocol tolerated the therapy well, with no significant safety concerns observed. The company is now engaging with the FDA to align on the path to completing the trial.

Key Details

• Trial Update: The first three patients in the global, pivotal Phase 2 trial were treated safely with RP-A501 under a modified protocol.
• Safety Profile: No thrombotic microangiopathy (TMA), capillary leak syndrome, or other significant safety concerns were observed.
• Next Steps: Rocket is working with the FDA to finalize the path for dosing additional patients and completing the trial, with a regulatory pathway update expected in the second half of 2026.